knowledge -WSS

knowledge

author：knowledge 2025-09-02 22:26:34 - browse：635

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Biogen nominates mother of director’s child to replace him on board

hotspot

knowledge

WSS

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Mom launches Girl Scout troop for LGBTQ youth in Texas

House looks to weaken Medicare negotiation

Pfizer highlights cancer drugs it thinks could reignite investor interest

Why getting cancer drugs just got harder for rural patients

How to fix the rural physician shortage in the U.S.

focus

knowledge

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Apple is now the first public company to be valued at $3 trillion

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Walensky prepares to leave CDC — and Congress — behind

Biogen nominates mother of director’s child to replace him on board

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

Virginia high school admissions case could be legal follow

An inside look at PIPEs, biotech's buzzy new financing tool

focus

Bispecific antibodies are next new thing in cancer immunotherapy

Covid isolation guidance eased by the CDC

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

AstraZeneca loses challenge to Medicare drug price negotiation

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

A Q&A with Aletha Maybank, AMA’s chief health equity officer

focus

hotspot

knowledge

leisure time